Background Background Few studies have
Few studies have examined samples of people with examined samples of people with cannabis-induced psychotic symptoms. cannabis-induced psychotic symptoms.
Aims Aims To establish whether cannabis-
To establish whether cannabisinduced psychotic disorders are followed induced psychotic disorders are followed by development of persistent psychotic by development of persistent psychotic conditions, and the timing of their onset. conditions, and the timing of their onset.
Method Method Data on patients treated for
Data on patients treated for cannabis-induced psychotic symptoms cannabis-induced psychotic symptoms between1994 and1999 were extracted between1994 and1999 were extracted from the Danish Psychiatric Central from the Danish Psychiatric Central Register.Those previously treated for any Register.Those previously treated for any psychotic symptoms were excluded.The psychotic symptoms were excluded.The remaining 535 patients were followed for remaining 535 patients were followed for at least 3 years.In a separate analysis, the at least 3 years.In a separate analysis, the sample was compared with people sample was compared with people referred for schizophrenia-spectrum referred for schizophrenia-spectrum disorders for the first time, but who had disorders for the first time, but who had no history of cannabis-induced psychosis. no history of cannabis-induced psychosis.
Results
Results Schizophrenia-spectrum Schizophrenia-spectrum disorders were diagnosed in 44.5% of the disorders were diagnosed in 44.5% of the sample.New psychotic episodes of any sample.New psychotic episodes of any type were diagnosed in 77.2%.Male type were diagnosed in 77.2%.Male gender and young age were associated gender and young age were associated with increased risk.Development of with increased risk.Development of schizophrenia-spectrum disorders was schizophrenia-spectrum disorders was often delayed, and 47.1% of patients often delayed, and 47.1% of patients received a diagnosis more than a year after received a diagnosis more than a year after seeking treatment for a cannabis-induced seeking treatment for a cannabis-induced psychosis.The patients developed psychosis.The patients developed schizophrenia at an earlier age than people schizophrenia at an earlier age than people in the comparison group (males, 24.6 in the comparison group (males, 24.6 v v. . 30.7 years, females, 28.9 30.7 years, females, 28.9 v v. 33.1years) . . 33.1years).
Conclusions
Conclusions Cannabis-induced Cannabis-induced psychotic disorders are of greatclinical and psychotic disorders are of greatclinical and prognostic importance. prognostic importance.
Declaration of interest Declaration of interest None.
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Little is known about the clinical implicaLittle is known about the clinical implications and prognostic significance of tions and prognostic significance of cannabis-induced psychotic symptoms, cannabis-induced psychotic symptoms, despite the fact that cannabis has been despite the fact that cannabis has been closely linked with the development of closely linked with the development of schizophrenia (Arseneault schizophrenia (Arseneault et al et al, 2004) . . It is well established that psychotic symptoms is well established that psychotic symptoms may follow cannabis intake, and a number may follow cannabis intake, and a number of reviews have concluded that such of reviews have concluded that such symptoms are generally short-lived and that symptoms are generally short-lived and that total remission can be expected (Tunving, total remission can be expected (Tunving, 1985; Thomas, 1993; Hall 1985; Thomas, 1993; . However, the & Degenhardt, 2004) . However, the transient nature of the symptoms and the transient nature of the symptoms and the favourable prognosis have only been evalufavourable prognosis have only been evaluated in case studies, and none of these has ated in case studies, and none of these has reported long-term follow-up data. reported long-term follow-up data.
In this study we use an epidemiological In this study we use an epidemiological approach to describe a substantial number approach to describe a substantial number of patients treated for cannabis-induced of patients treated for cannabis-induced psychotic disorder with no prior history of psychotic disorder with no prior history of psychotic symptoms. Patients were psychotic symptoms. Patients were followed for at least 3 years, with the aim followed for at least 3 years, with the aim of determining the proportion and types of determining the proportion and types of subsequent schizophrenia-spectrum of subsequent schizophrenia-spectrum disorders, the timing of onset, and whether disorders, the timing of onset, and whether the patients developed these conditions at the patients developed these conditions at an earlier age than other patients with an earlier age than other patients with schizophrenia but with no history of schizophrenia but with no history of cannabis-induced psychotic symptoms. cannabis-induced psychotic symptoms.
METHOD METHOD Sample Sample
The first analyses describe follow-up data The first analyses describe follow-up data for a cohort of patients treated for for a cohort of patients treated for cannabis-induced symptoms. These cannabis-induced symptoms. These patients were included if they had received patients were included if they had received treatment at a Danish psychiatric hospital treatment at a Danish psychiatric hospital with a diagnosis of cannabis-induced with a diagnosis of cannabis-induced psychotic disorder (code F12.5 in ICD-10; psychotic disorder (code F12.5 in ICD-10; World Health Organization, 1992 ) World Health Organization, 1992 between 1 January 1994 and 1 July 1999. between 1 January 1994 and 1 July 1999. Patients previously treated for any type of Patients previously treated for any type of psychotic symptoms or bipolar disorder psychotic symptoms or bipolar disorder were excluded. The included patients were were excluded. The included patients were followed for at least 3 years, and the followed for at least 3 years, and the end-point for the whole sample was 1 July end-point for the whole sample was 1 July 2002. Data for those who died between 2002. Data for those who died between 1 January 1994 and 1 July 2002 were 1 January 1994 and 1 July 2002 were censored. censored.
The second analysis was concerned The second analysis was concerned with the average age at the time with the average age at the time schizophrenia-spectrum disorders were first schizophrenia-spectrum disorders were first diagnosed. The cannabis group was comdiagnosed. The cannabis group was compared with a group consisting of all firstpared with a group consisting of all firsttime referrals with schizophrenia-spectrum time referrals with schizophrenia-spectrum disorders between 2002 and 2003, with disorders between 2002 and 2003, with no history of cannabis-induced psychotic no history of cannabis-induced psychotic symptoms. In the comparison group, those symptoms. In the comparison group, those with a history of psychotic episodes accordwith a history of psychotic episodes according to ICD-8 (assigned before 1994) were ing to ICD-8 (assigned before 1994) were also excluded. The latter exclusion criterion also excluded. The latter exclusion criterion was necessary because the diagnostic catewas necessary because the diagnostic categories from ICD-8 cannot be translated gories from ICD-8 cannot be translated into ICD-10 diagnoses in a meaningful into ICD-10 diagnoses in a meaningful way. way.
The registers The registers
Data were extracted from the Danish Data were extracted from the Danish Psychiatric Central Register. This register Psychiatric Central Register. This register contains information on all treatment contains information on all treatment provided by Danish psychiatric hospitals provided by Danish psychiatric hospitals and departments since 1970. Out-patient and departments since 1970. Out-patient treatment has only been registered since treatment has only been registered since 1995. After each contact with the psychi-1995. After each contact with the psychiatric system patients receive a diagnosis atric system patients receive a diagnosis code. Up to 1993 these were assigned using code. Up to 1993 these were assigned using ICD-8, and thereafter ICD-10 has been ICD-8, and thereafter ICD-10 has been used; ICD-9 was never in use in Denmark. used; ICD-9 was never in use in Denmark.
Only psychiatrists responsible for the Only psychiatrists responsible for the treatment are allowed to enter diagnoses treatment are allowed to enter diagnoses into the register. They generally have into the register. They generally have knowledge of prior hospitalisations and knowledge of prior hospitalisations and diagnoses based on case files and use this diagnoses based on case files and use this information in their evaluation of the information in their evaluation of the patients. There are no private psychiatric patients. There are no private psychiatric facilities in Denmark and treatment is free facilities in Denmark and treatment is free of charge. Information on patients who of charge. Information on patients who died during the study period was retrieved died during the study period was retrieved from the Danish Cause of Death Registry. from the Danish Cause of Death Registry. Registrations are person identifiable using Registrations are person identifiable using the Central Persons Register Number. This the Central Persons Register Number. This is a unique number given to every Danish is a unique number given to every Danish citizen at birth or at time of migration, citizen at birth or at time of migration, and it is used in all official registers in and it is used in all official registers in Denmark. Knowledge of this number Denmark. Knowledge of this number allows age and gender to be determined. allows age and gender to be determined.
Analysis Analysis
For this study the outcome 'schizophreniaFor this study the outcome 'schizophreniaspectrum disorders' was defined as schizospectrum disorders' was defined as schizophrenia (ICD-10 code F20), schizotypal phrenia (ICD-10 code F20), schizotypal disorder (ICD-10 code F21) and schizodisorder (ICD-10 code F21) and schizoaffective disorders (ICD-10 code F25). affective disorders (ICD-10 code F25). Separate analyses were made for other Separate analyses were made for other psychotic conditions. Most patients repsychotic conditions. Most patients received several different diagnoses during ceived several different diagnoses during the course of the follow-up. Treatment the course of the follow-up. Treatment episodes after index were therefore put into episodes after index were therefore put into a hierarchy. Schizophrenia-spectrum disa hierarchy. Schizophrenia-spectrum disorders were given highest priority, followed orders were given highest priority, followed by the remaining F20 diagnoses, bipolar by the remaining F20 diagnoses, bipolar disorder, acute and transient psychotic disorder, acute and transient psychotic conditions, substance-induced psychotic conditions, substance-induced psychotic disorders, and other diagnoses (predomidisorders, and other diagnoses (predominantly mood, anxiety and personality nantly mood, anxiety and personality disorders). disorders).
In the analysis of timing of onset of In the analysis of timing of onset of schizophrenia-spectrum disorders, the time schizophrenia-spectrum disorders, the time lapse between index and first referral with lapse between index and first referral with such diagnoses was recorded. The average such diagnoses was recorded. The average age at first referral with a schizophreniaage at first referral with a schizophreniaspectrum disorder among patients with a spectrum disorder among patients with a history of cannabis-induced psychoses history of cannabis-induced psychoses was compared with that of others who was compared with that of others who developed a schizophrenia-spectrum disdeveloped a schizophrenia-spectrum disorder order but had no recorded history of but had no recorded history of cannabiscannabis-induced psychotic symptoms.
induced psychotic symptoms.
Statistics Statistics
Model checking showed that the distribuModel checking showed that the distributions for age and number of subsequent tions for age and number of subsequent referrals were skewed. Log Gaussian rereferrals were skewed. Log Gaussian regression models were therefore used, and gression models were therefore used, and the back-transformed estimates and conthe back-transformed estimates and confidence intervals are reported. The effects fidence intervals are reported. The effects of age and gender on risk of subsequent of age and gender on risk of subsequent schizophrenia-spectrum disorder were schizophrenia-spectrum disorder were evaluated using Cox regression. A survival evaluated using Cox regression. A survival curve, showing the time from index to first curve, showing the time from index to first treatment for a schizophrenia-spectrum distreatment for a schizophrenia-spectrum disorder, was estimated for each gender using order, was estimated for each gender using a Cox regression model adjusting for age. a Cox regression model adjusting for age. Because of unequal variance of age between Because of unequal variance of age between the patients and the comparison group, the patients and the comparison group, Satterthwaite approximated degrees of Satterthwaite approximated degrees of freedom were used in the freedom were used in the t t-tests comparing -tests comparing age at first episode of various psychotic age at first episode of various psychotic conditions. Stata Statistical Software conditions. Stata Statistical Software release 8.0 was used for all analyses. release 8.0 was used for all analyses.
RESULTS RESULTS

Patient characteristics Patient characteristics
A total of 803 patients received treatment A total of 803 patients received treatment for cannabis-induced psychotic disorders for cannabis-induced psychotic disorders in Danish psychiatric hospitals between in Danish psychiatric hospitals between 1 January 1994 and 1 July 1999. With a 1 January 1994 and 1 July 1999. With a national population of approximately 5.4 national population of approximately 5.4 million people (Danmarks Statistik, 2004) , million people (Danmarks Statistik, 2004) , this results in an average incidence ratio this results in an average incidence ratio of 2.7 per 100 000 person-years. Prior of 2.7 per 100 000 person-years. Prior treatment for psychotic symptoms was treatment for psychotic symptoms was recorded for 240 patients, and in 28 cases recorded for 240 patients, and in 28 cases the diagnosis was changed into a the diagnosis was changed into a schizophrenia-spectrum disorder before schizophrenia-spectrum disorder before discharge. These cases were excluded. The discharge. These cases were excluded. The remaining 535 cases (66.6%) recorded no remaining 535 cases (66.6%) recorded no history of psychotic symptoms and were history of psychotic symptoms and were included for further analysis. included for further analysis.
The mean age at time of first treatment The mean age at time of first treatment for cannabis-induced symptoms was 27.0 for cannabis-induced symptoms was 27.0 years (s.d. years (s.d.¼7.7, 25th percentile 7.7, 25th percentile¼20.9, 20.9, median median¼25.5, 75th percentile 25.5, 75th percentile¼31.2); 441 31.2); 441 (82.4%) were male. A total of 379 patients (82.4%) were male. A total of 379 patients were admitted to hospital for a median stay were admitted to hospital for a median stay of 13 days (25th percentile of 13 days (25th percentile¼4, 75th 4, 75th percentile percentile¼29, mean 29, mean¼30.6) and 156 30.6) and 156 patients received out-patient treatment patients received out-patient treatment only. The mean length of follow-up was only. The mean length of follow-up was 5.9 years (s.d. 5.9 years (s.d.¼1.7). Twenty-two patients 1.7). Twenty-two patients died during the follow-up period, 13 within died during the follow-up period, 13 within 3 years of index and 9 after. Causes of 3 years of index and 9 after. Causes of death were suicide ( death were suicide (n n¼7), accident ( 7), accident (n n¼4), 4), natural causes ( natural causes (n n¼4) and unknown ( 4) and unknown (n n¼7). 7). Of the 13 who died within 3 years, 7 had been Of the 13 who died within 3 years, 7 had been diagnosed with a schizophrenia-spectrum diagnosed with a schizophrenia-spectrum disorder. Of the remaining 9 patients, 6 disorder. Of the remaining 9 patients, 6 received such diagnoses before death. received such diagnoses before death.
There were 2721 patients in the comThere were 2721 patients in the comparison group. In this group the mean age parison group. In this group the mean age at onset of schizophrenia-spectrum disat onset of schizophrenia-spectrum disorders was 33.8 years (s. P5 50.002). Young age 0.002). Young age was also related to increased risk. Conwas also related to increased risk. Controlling for gender, the proportional trolling for gender, the proportional hazard ratio when increasing the age by hazard ratio when increasing the age by 1 year was 0.97 (95% CI 0.95-0.99, 1 year was 0.97 (95% CI 0.95-0.99, P P5 50.003). 0.003).
Subsequent psychotic conditions Subsequent psychotic conditions
Number of subsequent Number of subsequent treatment episodes treatment episodes
The average number of treatment episodes The average number of treatment episodes caused by schizophrenia-spectrum disorders caused by schizophrenia-spectrum disorders was estimated for the 238 patients who was estimated for the 238 patients who developed these conditions. The mean developed these conditions. The mean number was 1.2 per person-year (95% CI number was 1.2 per person-year (95% CI 1.0-1.4) for men and 0.7 per person-year 1.0-1.4) for men and 0.7 per person-year (95% CI 0.4-1.1) for women. Altogether (95% CI 0.4-1.1) for women. Altogether 176 patients (73.9%) received treatment 176 patients (73.9%) received treatment 511 511 AUTHOR'S PROOF AUTHOR'S PROOF for a schizophrenia-spectrum disorder on for a schizophrenia-spectrum disorder on three or more separate occasions after three or more separate occasions after index. index.
Pattern of subsequent diagnoses Pattern of subsequent diagnoses
Most patients were treated many times Most patients were treated many times during follow-up, and the diagnoses often during follow-up, and the diagnoses often changed. Table 2 presents the prevalence changed. Table 2 presents the prevalence rates for the entire population of 535 rates for the entire population of 535 patients. Paranoid schizophrenia was the patients. Paranoid schizophrenia was the most common condition, followed by acute most common condition, followed by acute and transient psychotic disorders, personaland transient psychotic disorders, personality disorders and unspecified schizophrenia. ity disorders and unspecified schizophrenia. A separate analysis was performed of the A separate analysis was performed of the last schizophrenia-spectrum diagnosis for last schizophrenia-spectrum diagnosis for each patient within the observation period each patient within the observation period (results not shown). This revealed that, of (results not shown). This revealed that, of the 238 patients who received such diagthe 238 patients who received such diagnoses, 58.0% were treated for paranoid noses, 58.0% were treated for paranoid schizophrenia at the most recent contact schizophrenia at the most recent contact with a psychiatric department and 20.2% with a psychiatric department and 20.2% were treated for unspecified schizophrenia. were treated for unspecified schizophrenia. In total, 211 (88.7%) of the patients sought In total, 211 (88.7%) of the patients sought treatment for schizophrenia at their latest treatment for schizophrenia at their latest contact with the psychiatric care system. contact with the psychiatric care system.
Timing of onset Timing of onset
The first episode of schizophrenia-spectrum The first episode of schizophrenia-spectrum disorder occurred after a substantial delay disorder occurred after a substantial delay for most of the 238 patients (Fig. 1) . It for most of the 238 patients (Fig. 1) . It was registered more than 1 year after index was registered more than 1 year after index for 47.1% of the patients, and 17.2% defor 47.1% of the patients, and 17.2% developed such conditions more than 3 years veloped such conditions more than 3 years later. later.
Age at onset Age at onset
The mean age at first treatment for a The mean age at first treatment for a schizophrenia-spectrum disorder among schizophrenia-spectrum disorder among the patients was compared with that of a the patients was compared with that of a comparison group receiving treatment for comparison group receiving treatment for the same conditions for the first time in the same conditions for the first time in 2002 and 2003, but with no prior history 2002 and 2003, but with no prior history of cannabis-induced psychotic symptoms. of cannabis-induced psychotic symptoms. Both men and women in the cannabis Both men and women in the cannabis group were younger at the first time they group were younger at the first time they were diagnosed with schizophrenia were diagnosed with schizophrenia (Table 3) . For people who developed schi-( 
DISCUSSION DISCUSSION
The prognostic significance of cannabisThe prognostic significance of cannabisinduced psychoses is not well established. induced psychoses is not well established. There is general agreement that such condiThere is general agreement that such conditions are rare (e.g. DSM-IV; American tions are rare (e.g. DSM-IV; American Psychiatric Association, 1994); however, Psychiatric Association, 1994); however, our study is the first to provide an estimate our study is the first to provide an estimate of the incidence rate. Indeed, Hall & of the incidence rate. Indeed, found reports of only found reports of only 397 cases of 'cannabis psychosis' in a re-397 cases of 'cannabis psychosis' in a review on the topic. This probably explains view on the topic. This probably explains why the methodological quality of previous why the methodological quality of previous investigations has been criticised in several investigations has been criticised in several reviews (Thornicroft, 1990; Thomas, reviews (Thornicroft, 1990; Thomas, 1993; Poole & Brabbins, 1996; Johns, 1993; Poole & Brabbins, 1996; . Most 2001; . Most are case studies or include few participants, are case studies or include few participants, and the follow-up intervals have been and the follow-up intervals have been limited in the longitudinal studies. Some limited in the longitudinal studies. Some 512 512 AUTHOR'S PROOF AUTHOR'S PROOF Fig. 1 Fig. 1 Time from index to first episode of schizophrenia-spectrum disorder (adjusted for age).
Time from index to first episode of schizophrenia-spectrum disorder (adjusted for age).
investigations concern patients with preinvestigations concern patients with preexisting schizophrenia or other severe menexisting schizophrenia or other severe mental illnesses, and in many studies the mental tal illnesses, and in many studies the mental status of the patients prior to the cannabisstatus of the patients prior to the cannabisinduced symptoms is uncertain. Our invesinduced symptoms is uncertain. Our investigation included 535 people with no prior tigation included 535 people with no prior history of psychosis who were followed history of psychosis who were followed for at least 3 years. This underlines the sigfor at least 3 years. This underlines the significance of the results. nificance of the results.
Outcome Outcome
It was established that almost half of It was established that almost half of the patients in our study treated for a the patients in our study treated for a cannabis-induced psychotic disorder develcannabis-induced psychotic disorder developed a schizophrenia-spectrum disorder oped a schizophrenia-spectrum disorder subsequently. A substantial number of subsequently. A substantial number of patients were diagnosed with paranoid patients were diagnosed with paranoid schizophrenia, and the vast majority of schizophrenia, and the vast majority of those who developed a schizophreniathose who developed a schizophreniaspectrum disorder were given this diagnosis spectrum disorder were given this diagnosis at the most recent hospitalisation. New at the most recent hospitalisation. New psychotic episodes developed in 77.2% of psychotic episodes developed in 77.2% of the entire sample and only 15.9% did not the entire sample and only 15.9% did not receive psychiatric treatment at any point receive psychiatric treatment at any point after index. Male gender and young age after index. Male gender and young age were associated with more severe outwere associated with more severe outcome. Most patients were treated on come. Most patients were treated on numerous occasions for schizophrenianumerous occasions for schizophreniaspectrum disorders, and in almost half of spectrum disorders, and in almost half of the cases the first episode occurred with a the cases the first episode occurred with a delay of more than a year. Compared with delay of more than a year. Compared with patients without a history of cannabispatients without a history of cannabisinduced psychosis, they developed schizoinduced psychosis, they developed schizophrenia at a significantly younger age. This phrenia at a significantly younger age. This effect was most marked for paranoid effect was most marked for paranoid schizophrenia. schizophrenia. For the majority of patients, cannabisFor the majority of patients, cannabisinduced psychotic symptoms proved to induced psychotic symptoms proved to be a first step in the development of a be a first step in the development of a schizophrenia-spectrum disorder or other schizophrenia-spectrum disorder or other severe psychopathology. This is inconsissevere psychopathology. This is inconsistent with findings from previous studies tent with findings from previous studies generally reporting complete remission generally reporting complete remission when patients abstain from further cannawhen patients abstain from further cannabis use (Talbott & Teague, 1969; Kolansky bis use (Talbott & Teague, 1969; Kolansky & Moore, 1971; Thacore, 1973; Thacore & Moore, 1971; Thacore, 1973; Thacore & Shukla, 1976; Rottanburg & Shukla, 1976; Rottanburg et al et al, 1982; , 1982; Carney Carney et al et al, 1984; Co-, 1984; Cohen & Johnson, 1988; Chaudry hen & Johnson, 1988; Chaudry et al et al, 1991; Wylie, 1995; Basu Wylie, 1995; Basu et al et al, 1999) , although , 1999), although some have reported that a minority of pasome have reported that a minority of patients with pre-existing mental problems tients with pre-existing mental problems had a less favourable outcome (Bromberg, had a less favourable outcome (Bromberg, 1939; Bernhardson & Gunne, 1972; Ten-1939; Bernhardson & Gunne, 1972; Tennant & Groesbeck, 1972; Chopra & Smith, nant & Groesbeck, 1972; Chopra & Smith, 1974; Palsson 1974; På lsson et al et al, 1982) . However, pa-, 1982). However, patients had generally not been followed after tients had generally not been followed after the cannabis-induced psychotic condition the cannabis-induced psychotic condition remitted, and no study included data on remitted, and no study included data on all patients more than 3 months after the all patients more than 3 months after the end of treatment. Many of the same investiend of treatment. Many of the same investigations have reported that cannabisgations have reported that cannabisinduced psychoses subside more quickly induced psychoses subside more quickly than psychoses that are not substancethan psychoses that are not substanceinduced (Talbott & Teague, 1969; induced (Talbott & Teague, 1969; Bernhardson & Gunne, 1972; Tennant & Bernhardson & Gunne, 1972; Tennant & Groesbeck, 1972; Thacore, 1973; Chopra Groesbeck, 1972; Thacore, 1973; Chopra & Smith, 1974; Thacore & Shukla, 1976; & Smith, 1974; Thacore & Shukla, 1976; Palsson På lsson et al et al, 1982; Rottanburg , 1982; Rottanburg et al et al, , 1982; Carney 1982; Carney et al et al, 1984; Drummond, , 1984; Cohen & Johnson, 1988; Chaudry 1986; Cohen & Johnson, 1988; Chaudry et al et al, 1991; Wylie, 1995; Basu , 1991; Wylie, 1995; Basu et al et al, , 1999) . This is consistent with findings in 1999). This is consistent with findings in our study. Many patients received outour study. Many patients received outpatient treatment only, and the length of patient treatment only, and the length of stay was generally short for those who were stay was generally short for those who were admitted to hospital. Combining these facadmitted to hospital. Combining these factors probably explains why the evaluation tors probably explains why the evaluation of the outcome in this study differs so of the outcome in this study differs so markedly from other studies. The lack of markedly from other studies. The lack of long-term follow-up of the patients means long-term follow-up of the patients means that delayed onset of severe psychopatholothat delayed onset of severe psychopathological symptoms might have been undetected gical symptoms might have been undetected in previous studies. in previous studies.
Existence of 'cannabis psychosis' Existence of 'cannabis psychosis'
In accordance with our results, some In accordance with our results, some authors have claimed that cannabisauthors have claimed that cannabisinduced psychotic symptoms are often a induced psychotic symptoms are often a sign of underlying psychopathology and sign of underlying psychopathology and that the condition is easily confused with that the condition is easily confused with schizophrenia (Weil, 1970; Thornicroft, schizophrenia (Weil, 1970; Thornicroft, 1990; Thomas, 1993; Poole & Brabbins, 1990; Thomas, 1993; Poole & Brabbins, 1996) . However, data have been lacking 1996). However, data have been lacking in attempts to substantiate this. Criticism in attempts to substantiate this. Criticism has centred on the concept of 'cannabis has centred on the concept of 'cannabis psychosis', and has primarily been based psychosis', and has primarily been based on studies failing to show a symptom proon studies failing to show a symptom profile distinct from other psychoses (Imade file distinct from other psychoses Mathers & Ghodse, 1992; Mathers & Ghodse, 1992; McGuire McGuire et al et al, 1995) . Numerous symptom , 1995). Numerous symptom clusters have been described as characterisclusters have been described as characteristic of 'cannabis psychosis', and an exact tic of 'cannabis psychosis', and an exact meaning of the concept has never been meaning of the concept has never been established (Thornicroft, 1990; Hall & established (Thornicroft, 1990; . However, even the Degenhardt, 2004). However, even the critics have accepted that psychotic sympcritics have accepted that psychotic symptoms can be induced by cannabis, and that toms can be induced by cannabis, and that such symptoms generally wear off quickly such symptoms generally wear off quickly and with complete remission. It has never and with complete remission. It has never before been shown that cannabis-induced before been shown that cannabis-induced psychoses are followed by development of psychoses are followed by development of long-term psychotic conditions in people long-term psychotic conditions in people with no history of psychosis, and this is with no history of psychosis, and this is the first study to show that such symptoms, the first study to show that such symptoms, in most cases, can be regarded as the first in most cases, can be regarded as the first manifestations of long-term psychotic illmanifestations of long-term psychotic illness. The results do not disprove the exisness. The results do not disprove the existence of 'cannabis psychosis', but clearly tence of 'cannabis psychosis', but clearly show that cannabis-induced psychotic show that cannabis-induced psychotic symptoms must be regarded as important symptoms must be regarded as important risk factors for subsequent development of risk factors for subsequent development of schizophrenia-spectrum disorders. schizophrenia-spectrum disorders.
The question of causality The question of causality
Recent studies have established that Recent studies have established that cannabis use increases the risk of developcannabis use increases the risk of developing severe psychotic disorders (Arseneault ing severe psychotic disorders (Arseneault et al et al, 2004) , although the findings are not , 2004), although the findings are not conclusive (Macleod conclusive (Macleod et al et al, 2004) . Whether , 2004). Whether cannabis was causally linked with developcannabis was causally linked with development of schizophrenia among patients in ment of schizophrenia among patients in our investigation cannot be determined our investigation cannot be determined since, owing to the study design, it was since, owing to the study design, it was not possible to control for factors such as not possible to control for factors such as hereditary predisposition, other drug use hereditary predisposition, other drug use and socio-economic status. However, the and socio-economic status. However, the fact that patients with cannabis-induced fact that patients with cannabis-induced psychotic symptoms developed schizopsychotic symptoms developed schizophrenia at a younger age than patients with phrenia at a younger age than patients with no recorded history of cannabis-induced no recorded history of cannabis-induced psychosis indicates that cannabis use may psychosis indicates that cannabis use may hasten the pathogenesis. This is in accorhasten the pathogenesis. This is in accordance with a recent study showing that dance with a recent study showing that the age at onset of schizophrenia is lower the age at onset of schizophrenia is lower among patients using cannabis (Veen among patients using cannabis (Veen et al et al, , 2004 ) and further validates this significant 2004) and further validates this significant finding. finding. Cannabis use in Denmark Cannabis use in Denmark
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The incidence of cannabis-induced psyThe incidence of cannabis-induced psychotic disorders in Denmark was estimated chotic disorders in Denmark was estimated to be 2.7 per 100 000 person-years. This to be 2.7 per 100 000 person-years. This confirms that such conditions are rare. In confirms that such conditions are rare. In the interpretation of this number, it is the interpretation of this number, it is important to note that in Denmark important to note that in Denmark cannabis is predominantly smoked as cannabis is predominantly smoked as hashish, which is more potent than hashish, which is more potent than marijuana. A recent publication from the marijuana. A recent publication from the Danish National Board of Health (2003) Danish National Board of Health (2003) shows that 40.9% of all Danish citizens shows that 40.9% of all Danish citizens aged 16-24 years have used cannabis at aged 16-24 years have used cannabis at some point in their lifetime, and that some point in their lifetime, and that 19.7% had used the substance in the 19.7% had used the substance in the previous month. previous month.
Limitations Limitations
The results of this study must be evaluated The results of this study must be evaluated considering its limitations. Data were not considering its limitations. Data were not specifically collected for this investigation, specifically collected for this investigation, so it was not possible to validate the diagso it was not possible to validate the diagnosis of cannabis-induced psychosis. It nosis of cannabis-induced psychosis. It may be difficult to distinguish between this may be difficult to distinguish between this diagnosis and early signs of schizophrenia. diagnosis and early signs of schizophrenia. However, many patients only received However, many patients only received out-patient treatment for the cannabisout-patient treatment for the cannabisinduced symptoms, and for those who were induced symptoms, and for those who were admitted to hospital the length of stay was admitted to hospital the length of stay was typically short. Furthermore, there was a typically short. Furthermore, there was a substantial delay before schizophreniasubstantial delay before schizophreniaspectrum disorders emerged in most spectrum disorders emerged in most patients. This indicates that the cannabispatients. This indicates that the cannabisinduced symptoms were short-lived and induced symptoms were short-lived and that temporary remission was probably that temporary remission was probably achieved in most cases. achieved in most cases. It could not be ascertained that the It could not be ascertained that the patients fulfilled the diagnostic criteria for patients fulfilled the diagnostic criteria for schizophrenia-spectrum disorders either. schizophrenia-spectrum disorders either. Furthermore, we were not able to control Furthermore, we were not able to control for regular use of cannabis or other drugs, for regular use of cannabis or other drugs, such as stimulants, during the follow-up such as stimulants, during the follow-up period. It might be argued that the diagperiod. It might be argued that the diagnoses assigned to the patients during noses assigned to the patients during follow-up were merely new instances of follow-up were merely new instances of substance-induced symptoms being missubstance-induced symptoms being misclassified. On the other hand, the fact that classified. On the other hand, the fact that 73.9% of the patients were given 73.9% of the patients were given schizophrenia-spectrum diagnoses on at schizophrenia-spectrum diagnoses on at least three separate occasions is inconsistent least three separate occasions is inconsistent with this. In addition, psychiatrists use with this. In addition, psychiatrists use prior case records upon referral, so previous prior case records upon referral, so previous problems with substance misuse are likely problems with substance misuse are likely to be detected. Finally, it is standard proto be detected. Finally, it is standard procedure to enquire about substance use cedure to enquire about substance use among patients presenting with psychotic among patients presenting with psychotic symptoms. symptoms.
Some confounders might have influSome confounders might have influenced the evaluation of age at first enced the evaluation of age at first treatment for schizophrenia. It is well treatment for schizophrenia. It is well established that cannabis use is most established that cannabis use is most common among adolescents and young common among adolescents and young adults. If we suppose that cannabis use adults. If we suppose that cannabis use and schizophrenia are unrelated, and the and schizophrenia are unrelated, and the first signs of schizophrenia happen to first signs of schizophrenia happen to co-occur with cannabis use, then the sympco-occur with cannabis use, then the symptoms might erroneously be attributed to toms might erroneously be attributed to cannabis. If this were the case, it might lead cannabis. If this were the case, it might lead to bias when evaluating the age at first to bias when evaluating the age at first episode of schizophrenia in the cannabis episode of schizophrenia in the cannabis group. Other factors that we were not group. Other factors that we were not able to control for (e.g. socio-economic able to control for (e.g. socio-economic status and other drug use) might also have status and other drug use) might also have influenced these results. influenced these results.
Finally, the patients in our study Finally, the patients in our study possibly represent more severe cases of possibly represent more severe cases of cannabis-induced psychotic symptoms; cannabis-induced psychotic symptoms; therefore, the results may not generalise to therefore, the results may not generalise to people who develop psychotic symptoms people who develop psychotic symptoms that are less persistent, or who for other that are less persistent, or who for other reasons do not present for treatment. reasons do not present for treatment. Conversely, there is some indication that Conversely, there is some indication that any occurrence of psychotic symptoms after any occurrence of psychotic symptoms after cannabis intake could constitute a risk cannabis intake could constitute a risk for subsequent schizophrenia-spectrum disfor subsequent schizophrenia-spectrum disorders (Verdoux, 2004) . If this can be orders (Verdoux, 2004) . If this can be corroborated it would have clear implicacorroborated it would have clear implications for the ongoing search for early signs tions for the ongoing search for early signs of schizophrenia. This should be further of schizophrenia. This should be further investigated in the future. investigated in the future.
Implications Implications
Our study shows that cannabis-induced Our study shows that cannabis-induced psychotic symptoms are an important risk psychotic symptoms are an important risk factor for subsequent development of factor for subsequent development of severe psychopathological disorder. This is severe psychopathological disorder. This is in contrast to previous studies describing in contrast to previous studies describing the condition as harmless. Although it the condition as harmless. Although it cannot be determined that cannabis has a cannot be determined that cannabis has a causal impact on the subsequent developcausal impact on the subsequent development, the findings have clear implications ment, the findings have clear implications for clinicians who encounter a patient for clinicians who encounter a patient with cannabis-induced psychotic disorder. with cannabis-induced psychotic disorder. The prognosis for the patient is poor, The prognosis for the patient is poor, and attention needs to be given to early and attention needs to be given to early intervention. intervention. Clinicians should be aware that half of all patients treated for cannabis-induced psychosis will subsequently develop a schizophrenia-spectrum disorder; almost a psychosis will subsequently develop a schizophrenia-spectrum disorder; almost a third will be diagnosed with paranoid schizophrenia. third will be diagnosed with paranoid schizophrenia.
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